Report Detail

Other Global Venous thromboembolism(VTE)Therapeutics Market Insights, Forecast to 2025

  • RnM2324298
  • |
  • 16 May, 2019
  • |
  • Global
  • |
  • 117 pages
  • |
  • QYResearch
  • |
  • Other

Global Venous thromboembolism(VTE)Therapeutics Market Insights, Forecast to 2025

Table of Contents

    1 Study Coverage

    • 1.1 Venous thromboembolism(VTE)Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Venous thromboembolism(VTE)Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Deep Vein Thrombosis(DVT)
      • 1.4.3 Pulmonary Embolism(PE)
      • 1.4.4 Others
    • 1.5 Market by End User
      • 1.5.1 Global Venous thromboembolism(VTE)Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 ASCs
      • 1.5.4 Research Institutes
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Venous thromboembolism(VTE)Therapeutics Market Size
      • 2.1.1 Global Venous thromboembolism(VTE)Therapeutics Revenue 2014-2025
      • 2.1.2 Global Venous thromboembolism(VTE)Therapeutics Sales 2014-2025
    • 2.2 Venous thromboembolism(VTE)Therapeutics Growth Rate by Regions
      • 2.2.1 Global Venous thromboembolism(VTE)Therapeutics Sales by Regions
      • 2.2.2 Global Venous thromboembolism(VTE)Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Venous thromboembolism(VTE)Therapeutics Sales by Manufacturers
      • 3.1.1 Venous thromboembolism(VTE)Therapeutics Sales by Manufacturers
      • 3.1.2 Venous thromboembolism(VTE)Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Venous thromboembolism(VTE)Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Venous thromboembolism(VTE)Therapeutics Revenue by Manufacturers
      • 3.2.1 Venous thromboembolism(VTE)Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Venous thromboembolism(VTE)Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Venous thromboembolism(VTE)Therapeutics Price by Manufacturers
    • 3.4 Venous thromboembolism(VTE)Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Venous thromboembolism(VTE)Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Venous thromboembolism(VTE)Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Venous thromboembolism(VTE)Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Venous thromboembolism(VTE)Therapeutics Sales by Product
    • 4.2 Global Venous thromboembolism(VTE)Therapeutics Revenue by Product
    • 4.3 Venous thromboembolism(VTE)Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Venous thromboembolism(VTE)Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Venous thromboembolism(VTE)Therapeutics by Countries
      • 6.1.1 North America Venous thromboembolism(VTE)Therapeutics Sales by Countries
      • 6.1.2 North America Venous thromboembolism(VTE)Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Venous thromboembolism(VTE)Therapeutics by Product
    • 6.3 North America Venous thromboembolism(VTE)Therapeutics by End User

    7 Europe

    • 7.1 Europe Venous thromboembolism(VTE)Therapeutics by Countries
      • 7.1.1 Europe Venous thromboembolism(VTE)Therapeutics Sales by Countries
      • 7.1.2 Europe Venous thromboembolism(VTE)Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Venous thromboembolism(VTE)Therapeutics by Product
    • 7.3 Europe Venous thromboembolism(VTE)Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Venous thromboembolism(VTE)Therapeutics by Countries
      • 8.1.1 Asia Pacific Venous thromboembolism(VTE)Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Venous thromboembolism(VTE)Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Venous thromboembolism(VTE)Therapeutics by Product
    • 8.3 Asia Pacific Venous thromboembolism(VTE)Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Venous thromboembolism(VTE)Therapeutics by Countries
      • 9.1.1 Central & South America Venous thromboembolism(VTE)Therapeutics Sales by Countries
      • 9.1.2 Central & South America Venous thromboembolism(VTE)Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Venous thromboembolism(VTE)Therapeutics by Product
    • 9.3 Central & South America Venous thromboembolism(VTE)Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Venous thromboembolism(VTE)Therapeutics by Countries
      • 10.1.1 Middle East and Africa Venous thromboembolism(VTE)Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Venous thromboembolism(VTE)Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Venous thromboembolism(VTE)Therapeutics by Product
    • 10.3 Middle East and Africa Venous thromboembolism(VTE)Therapeutics by End User

    11 Company Profiles

    • 11.1 Boehringer Ingelheim
      • 11.1.1 Boehringer Ingelheim Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Boehringer Ingelheim Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Boehringer Ingelheim Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.1.5 Boehringer Ingelheim Recent Development
    • 11.2 Bayer
      • 11.2.1 Bayer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bayer Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bayer Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.2.5 Bayer Recent Development
    • 11.3 Janssen
      • 11.3.1 Janssen Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Janssen Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Janssen Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.3.5 Janssen Recent Development
    • 11.4 Bristol-Myers Squibb
      • 11.4.1 Bristol-Myers Squibb Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Bristol-Myers Squibb Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Bristol-Myers Squibb Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.4.5 Bristol-Myers Squibb Recent Development
    • 11.5 Pfizer
      • 11.5.1 Pfizer Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Pfizer Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Pfizer Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.5.5 Pfizer Recent Development
    • 11.6 Daiichi-Sankyo
      • 11.6.1 Daiichi-Sankyo Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Daiichi-Sankyo Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Daiichi-Sankyo Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.6.5 Daiichi-Sankyo Recent Development
    • 11.7 Portola Pharmaceuticals
      • 11.7.1 Portola Pharmaceuticals Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Portola Pharmaceuticals Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Portola Pharmaceuticals Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.7.5 Portola Pharmaceuticals Recent Development
    • 11.8 Armetheon
      • 11.8.1 Armetheon Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Armetheon Venous thromboembolism(VTE)Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Armetheon Venous thromboembolism(VTE)Therapeutics Products Offered
      • 11.8.5 Armetheon Recent Development

    12 Future Forecast

    • 12.1 Venous thromboembolism(VTE)Therapeutics Market Forecast by Regions
      • 12.1.1 Global Venous thromboembolism(VTE)Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Venous thromboembolism(VTE)Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Venous thromboembolism(VTE)Therapeutics Market Forecast by Product
      • 12.2.1 Global Venous thromboembolism(VTE)Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Venous thromboembolism(VTE)Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Venous thromboembolism(VTE)Therapeutics Market Forecast by End User
    • 12.4 North America Venous thromboembolism(VTE)Therapeutics Forecast
    • 12.5 Europe Venous thromboembolism(VTE)Therapeutics Forecast
    • 12.6 Asia Pacific Venous thromboembolism(VTE)Therapeutics Forecast
    • 12.7 Central & South America Venous thromboembolism(VTE)Therapeutics Forecast
    • 12.8 Middle East and Africa Venous thromboembolism(VTE)Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Venous thromboembolism(VTE)Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE 
      One of the Major drivers of VTE market growth over the forecast period is the increase in patient shares towards the NOACs due to increased confidence among physicians about using these novel therapies.
      The global Venous thromboembolism(VTE)Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Venous thromboembolism(VTE)Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Venous thromboembolism(VTE)Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Venous thromboembolism(VTE)Therapeutics in these regions.
      This research report categorizes the global Venous thromboembolism(VTE)Therapeutics market by top players/brands, region, type and end user. This report also studies the global Venous thromboembolism(VTE)Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Boehringer Ingelheim
      Bayer
      Janssen
      Bristol-Myers Squibb
      Pfizer
      Daiichi-Sankyo
      Portola Pharmaceuticals
      Armetheon

      Market size by Product
      Deep Vein Thrombosis(DVT)
      Pulmonary Embolism(PE)
      Others
      Market size by End User
      Hospital
      ASCs
      Research Institutes

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Venous thromboembolism(VTE)Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Venous thromboembolism(VTE)Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Venous thromboembolism(VTE)Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Venous thromboembolism(VTE)Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Venous thromboembolism(VTE)Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Venous thromboembolism(VTE)Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Venous thromboembolism(VTE)Therapeutics . Industry analysis & Market Report on Venous thromboembolism(VTE)Therapeutics is a syndicated market report, published as Global Venous thromboembolism(VTE)Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Venous thromboembolism(VTE)Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $4,900.00
      $7,350.00
      $9,800.00
      3,864.30
      5,796.45
      7,728.60
      4,380.96
      6,571.44
      8,761.92
      536,986.10
      805,479.15
      1,073,972.20
      341,269.81
      511,904.72
      682,539.62
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report